Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism

• Published in: Nature microbiology Vol. 7; no. 10; pp. 1605 - 1620
• Main Authors: Spanogiannopoulos, Peter, Kyaw, Than S., Guthrie, Ben G. H., Bradley, Patrick H., Lee, Joyce V., Melamed, Jonathan, Malig, Ysabella Noelle Amora, Lam, Kathy N., Gempis, Daryll, Sandy, Moriah, Kidder, Wesley, Van Blarigan, Erin L., Atreya, Chloe E., Venook, Alan, Gerona, Roy R., Goga, Andrei, Pollard, Katherine S., Turnbaugh, Peter J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.10.2022; Nature Publishing Group
• Subjects: 38; 38/91; 45/23; 5-Fluorouracil; 631/326/2565/2134; 631/67/70; 64/60; 692/4017; 82; 82/58; Animals; Antibacterial activity; Antineoplastic Agents - metabolism; Antineoplastic Agents - pharmacology; Antitumor agents; Bacteria - genetics; Bioavailability; Biomedical and Life Sciences; Cancer; Colorectal carcinoma; Drug metabolism; Escherichia coli; Escherichia coli - genetics; Escherichia coli - metabolism; Fluorouracil - metabolism; Fluorouracil - pharmacology; Humans; Infectious Diseases; Intestinal microflora; Life Sciences; Mammalian cells; Mammals; Medical Microbiology; Metabolic Networks and Pathways; Metabolic pathways; Metabolism; Metabolites; Mice; Microbiology; Microbiomes; Parasitology; Virology

Pharmaceuticals have extensive reciprocal interactions with the microbiome, but whether bacterial drug sensitivity and metabolism is driven by pathways conserved in host cells remains unclear. Here we show that anti-cancer fluoropyrimidine drugs inhibit the growth of gut bacterial strains from 6 phy...